<DOC>
	<DOC>NCT00310492</DOC>
	<brief_summary>This trial is performed to assess the efficacy and safety of ALK-depot SQ mites for treatment of atopic dermatitis</brief_summary>
	<brief_title>Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Positive specific IgE to house dust mites Atopic dermatitis according to Hanifin/Rajka Chronic course of Atopic dermatitis SCORAD larger than 25 points Erythrodermia Syst.treatment with gcs or immunosuppressive agents in the prev.4 weeks History of specific immunotherapy with mites UV radiation Group 4 topical corticosteroids (European classification)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>